TRPA1 is a calcium-permeable nonselective cation channel functioning primarily as a polymodal chemosensor and nociceptor 1. It mediates pain detection through activation by structurally diverse stimuli including electrophilic compounds (allylthiocyanate, cinnamaldehyde) and pro-inflammatory mediators like bradykinin 2, as well as non-electrophilic agonists such as cannabinoids and menthol 1. TRPA1 activation causes calcium and sodium influx, triggering membrane depolarization and neuropeptide release in sensory neurons 1. Beyond nociception, TRPA1 participates in cold sensation, though mammalian thermosensitivity remains controversial, while insect and bird variants demonstrate heat-activation 3. TRPA1 is expressed in nociceptive sensory neurons, keratinocytes, mast cells, and other immune cells, where it potentiates cutaneous neurogenic inflammation 4. Clinically, TRPA1 dysregulation contributes to chemotherapy-induced peripheral neuropathy, asthma, and chr8 pain conditions 567. Recent evidence reveals TRPA1 in renal tubular cells suppresses diabetic kidney disease progression via MAPK-TGF-β1 pathway inhibition 8. TRPA1 antagonists show therapeutic promise for pain management and airway inflammation 6, representing a novel drug target for neuropathic and inflammatory conditions.